Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst, Andrew Chase, Joannah Score, et al.
Nature Genetics (2010) Vol. 42, Iss. 8, pp. 722-726
Closed Access | Times Cited: 1108

Showing 1-25 of 1108 citing articles:

Regulation of chromatin by histone modifications
Andrew J. Bannister, Tony Kouzarides
Cell Research (2011) Vol. 21, Iss. 3, pp. 381-395
Open Access | Times Cited: 5242
The Polycomb complex PRC2 and its mark in life
Raphaël Margueron, Danny Reinberg
Nature (2011) Vol. 469, Iss. 7330, pp. 343-349
Open Access | Times Cited: 3063
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson, Tony Kouzarides
Cell (2012) Vol. 150, Iss. 1, pp. 12-27
Open Access | Times Cited: 2867
A decade of exploring the cancer epigenome — biological and translational implications
Stephen B. Baylin, Peter A. Jones
Nature reviews. Cancer (2011) Vol. 11, Iss. 10, pp. 726-734
Open Access | Times Cited: 2668
Histone methylation: a dynamic mark in health, disease and inheritance
Eric Lieberman Greer, Yang Shi
Nature Reviews Genetics (2012) Vol. 13, Iss. 5, pp. 343-357
Open Access | Times Cited: 2004
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 25, pp. 2379-2390
Open Access | Times Cited: 1851
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, et al.
Blood (2013) Vol. 122, Iss. 22, pp. 3616-3627
Open Access | Times Cited: 1711
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe, Heidi M. Ott, Gopinath Ganji, et al.
Nature (2012) Vol. 492, Iss. 7427, pp. 108-112
Closed Access | Times Cited: 1684
SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2
Jyoti Nangalia, Charles Massie, E. Joanna Baxter, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 25, pp. 2391-2405
Open Access | Times Cited: 1647
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab, et al.
New England Journal of Medicine (2011) Vol. 364, Iss. 26, pp. 2496-2506
Open Access | Times Cited: 1557
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Torsten Haferlach, Yasunobu Nagata, Vera Grossmann, et al.
Leukemia (2013) Vol. 28, Iss. 2, pp. 241-247
Open Access | Times Cited: 1420
Targeting EZH2 in cancer
Kimberly H. Kim, Charles W.M. Roberts
Nature Medicine (2016) Vol. 22, Iss. 2, pp. 128-134
Open Access | Times Cited: 1272
Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
Kelly Moran-Crusio, Linsey B. Reavie, Alan H. Shih, et al.
Cancer Cell (2011) Vol. 20, Iss. 1, pp. 11-24
Open Access | Times Cited: 1215
SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts
Elli Papaemmanuil, Mario Cazzola, Jacqueline Boultwood, et al.
New England Journal of Medicine (2011) Vol. 365, Iss. 15, pp. 1384-1395
Open Access | Times Cited: 1162
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M Bernt, Nan Zhu, Amit Sinha, et al.
Cancer Cell (2011) Vol. 20, Iss. 1, pp. 66-78
Open Access | Times Cited: 860
Interplay between the Cancer Genome and Epigenome
Hui Shen, Peter W. Laird
Cell (2013) Vol. 153, Iss. 1, pp. 38-55
Open Access | Times Cited: 848
RNA in cancer
Gregory J. Goodall, Vihandha O. Wickramasinghe
Nature reviews. Cancer (2020) Vol. 21, Iss. 1, pp. 22-36
Closed Access | Times Cited: 837
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg, Michael A. Koldobskiy, Anita Göndör
Nature Reviews Genetics (2016) Vol. 17, Iss. 5, pp. 284-299
Open Access | Times Cited: 765
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, et al.
Nature Chemical Biology (2012) Vol. 8, Iss. 11, pp. 890-896
Closed Access | Times Cited: 736
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1861-1869
Closed Access | Times Cited: 717
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Max Jan, Thomas M. Snyder, M. Ryan Corces, et al.
Science Translational Medicine (2012) Vol. 4, Iss. 149
Open Access | Times Cited: 690
Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put
Jeffrey A. Simon, Robert E. Kingston
Molecular Cell (2013) Vol. 49, Iss. 5, pp. 808-824
Open Access | Times Cited: 688
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces, Wan‐Jen Hong, Irving L. Weissman, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 7, pp. 2548-2553
Open Access | Times Cited: 673
Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Martin Sauvageau, Guy Sauvageau
Cell stem cell (2010) Vol. 7, Iss. 3, pp. 299-313
Open Access | Times Cited: 653
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih, Omar Abdel‐Wahab, Jay P. Patel, et al.
Nature reviews. Cancer (2012) Vol. 12, Iss. 9, pp. 599-612
Closed Access | Times Cited: 650
Page 1 - Next Page

Scroll to top